





INTRODUCTION

- HER2 alterations constitute a well-recognized oncogenic driver in lung cancer and are gaining increasing therapeutic significance in the evolving landscape of precision oncology

METHODS

- This retrospective study included consecutive HER2 positive lung cancer patients treated at community oncology centers in Western India between March 2018 and December 2025.
- Clinical data including molecular testing modalities, mutational profiles, and survival outcomes were extracted from electronic medical records. Survival outcomes were analyzed using the Kaplan-Meier method

RESULTS



CONCLUSION

- This study provides real-world evidence on the molecular characteristics, treatment patterns, and clinical outcomes of HER2-altered lung cancer in Indian community oncology settings, highlighting its evolving role in guiding precision-based therapeutic strategies.